Literature DB >> 3099750

Biosynthesis of complement C1 inhibitor by Hep G2 cells. Reactivity of different glycosylated forms of the inhibitor with C1s.

M H Prandini, A Reboul, M G Colomb.   

Abstract

The biosynthesis of C1 Inh (C1 inhibitor) was studied in a human hepatoma cell line (Hep G2) by metabolic labelling, immunoprecipitation with anti-(C1 Inh) serum, analysis on SDS/polyacrylamide gel slabs and fluorography. Two forms of C1 Inh are secreted by Hep G2: a minor form of Mr 90,000 and a major form of Mr approximately 100,000. The latter form is also found in small amounts intracellularly in co-existence with an 80,000-Mr form. Accumulation of the 80,000-Mr C1 Inh is favoured when the cells are labelled at 23 degrees C instead of 37 degrees C or when they are treated with monensin. In the presence of tunicamycin, a compound that blocks the formation of N-asparagine-linked oligosaccharide chains, a decrease in Mr of both secreted and intracellular major forms is observed, indicating that secreted and intracellular C1 Inh contain N-linked oligosaccharide units. The 100,000 Mr secreted C1 Inh is sensitive to endoglycosidase F but resistant to endoglycosidase H, and it incorporates [3H]galactose, [3H]glucosamine and [3H]galactosamine, indicating the presence of both N-linked oligosaccharides of the complex type and O-linked oligosaccharides. The intracellular C1 Inh contains N-linked oligosaccharide units of the high-mannose type as demonstrated by endoglycosidase H-sensitivity. The functional activity of C1 Inh during its biosynthesis was tested by studying its reactivity towards C1s. Both secreted and intracellular C1 Inh form covalent-like complexes with purified plasma C1s. The underglycosylated C1 Inh secreted in presence of tunicamycin is still reactive with purified C1s. These results clearly show that sugars are not essential for this inhibitory activity of C1 Inh.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3099750      PMCID: PMC1146951          DOI: 10.1042/bj2370093

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  33 in total

1.  A simplified procedure for the purification of C1-inactivator from human plasma. Interaction with complement subcomponents C1r and C1s.

Authors:  A Reboul; G J Arlaud; R B Sim; M G Colomb
Journal:  FEBS Lett       Date:  1977-07-01       Impact factor: 4.124

2.  [Isolation and characterization of C1-Inactivator from human plasma].

Authors:  H Haupt; N Heimburger; T Kranz; H G Schwick
Journal:  Eur J Biochem       Date:  1970-12

3.  C1 inhibitor: evidence for decreased hepatic synthesis in hereditary angioneurotic edema.

Authors:  A M Johnson; C A Alper; F S Rosen; J M Craig
Journal:  Science       Date:  1971-08-06       Impact factor: 47.728

4.  Interaction of plasma kallikrein with the C1 inhibitor.

Authors:  I Gigli; J W Mason; R W Colman; K F Austen
Journal:  J Immunol       Date:  1970-03       Impact factor: 5.422

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Interaction of 125I-labelled complement subcomponents C-1r and C-1s with protease inhibitors in plasma.

Authors:  R B Sim; A Reboul; G J Arlaud; C L Villiers; M G Colomb
Journal:  FEBS Lett       Date:  1979-01-01       Impact factor: 4.124

7.  Purification and properties of an endo-beta-N-acetylglucosaminidase from Streptomyces griseus.

Authors:  A L Tarentino; F Maley
Journal:  J Biol Chem       Date:  1974-02-10       Impact factor: 5.157

8.  Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin.

Authors:  P C Harpel; N R Cooper
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

9.  Tunicamycin, a new antibiotic. I. Isolation and characterization of tunicamycin.

Authors:  A Takatsuki; K Arima; G Tamura
Journal:  J Antibiot (Tokyo)       Date:  1971-04       Impact factor: 2.649

10.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

View more
  5 in total

1.  Dysfunctional C1 inhibitor Ta: deletion of Lys-251 results in acquisition of an N-glycosylation site.

Authors:  R B Parad; J Kramer; R C Strunk; F S Rosen; A E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

Review 2.  Complement biosynthesis by mononuclear phagocytes.

Authors:  A R McPhaden; K Whaley
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

3.  Proteolysis and deglycosylation of human C1 inhibitor. Effect on functional properties.

Authors:  A Reboul; M H Prandini; M G Colomb
Journal:  Biochem J       Date:  1987-05-15       Impact factor: 3.857

4.  Effect of interferon-gamma on complement gene expression in different cell types.

Authors:  D F Lappin; D Guc; A Hill; T McShane; K Whaley
Journal:  Biochem J       Date:  1992-01-15       Impact factor: 3.857

5.  A New Tool for Complement Research: In vitro Reconstituted Human Classical Complement Pathway.

Authors:  Michele Mutti; Katharina Ramoni; Gábor Nagy; Eszter Nagy; Valéria Szijártó
Journal:  Front Immunol       Date:  2018-12-04       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.